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medicine? The answer: focused, gender-specific, cardiovascular
clinical research.
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REPLY
In the gender subgroup analysis of the CURE (Clopidogrel in
Unstable Angina to Prevent Recurrent Events) trial data, we
observed that fewer women across all Thrombolysis In Myocardial
Infarction (TIMI) risk strata underwent coronary angiography
compared to men (1). However, among women who did have
significant coronary artery disease (CAD), an equal proportion
went on to have coronary revascularization compared to men. We
also noted, however, that women in the high-risk acute coronary
syndromes (ACS) group were significantly more likely to have
refractory angina or be readmitted to a hospital with recurrent
angina as compared to men. Dr. Kessler is correct that the
differences in revascularization rates could not account for the
difference in refractory ischemia/rehospitalization rates we ob-
served. However, if women were equally as likely to have coronary
angiograms as men, then more women with significant CAD may
have been identified. Subsequent revascularization in this high-risk
group may have equalized the rates of refractory ischemia between
women and men.
However, we recognize that our association represents a
subgroup analysis, which at best can raise a hypothesis but
cannot confirm whether it is true. Like Dr. Kessler, we also
advocate sex- and gender-based research in cardiovascular
disease using sufficient sample sizes and methodology to be
confirmatory.
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Troponin Trumps Common Sense
The state-of-the-art review of biomarkers in acute cardiac
disease by Drs. Jaffe, Babuin, and Apple is thoughtful and
timely (1). My concern, shared by many cardiologists, is that
troponin testing has gotten out of hand. Most cardiologists have
been asked to see a patient (often urgently) found to have a
mildly elevated troponin when the test was ordered reflexively—
regardless of the patient’s presenting complaints or past history.
Cardiologists on hospital services are tripping over troponin every
day. The most challenging situation is when a patient presents
with a serious (even life-threatening) noncardiac condition, and
one or more doctors involved in their care gets distracted by an
incidental mild troponin elevation. Occasionally, this leads to a
sudden obsession over one test result, a phenomenon I call
“troponin trumps common sense.”
Several problems are associated with the uninformed use of this
sensitive assay. The authors present information about the appro-
priate use of troponin testing that should be actively diffused into
practice. They write, “Because of the sensitivity of cTn [cardiac
troponin], elevations are common in patients with a large number
of acute and chronic cardiovascular diseases. It is up to the clinician
to decide whether the presentation is one of acute ischemia.”(1)
Table 2 (1) lists about two dozen situations where “elevations of
troponin in the absence of overt ischemic heart disease” occur.
Admittedly, most patients presenting with an acute coronary
syndrome (ACS) also have one or more of the conditions listed.
This is where clinical judgment counts. The patients I am
describing do not present with chest pain, dyspnea, or other
symptoms and signs, or an electrocardiogram suggesting an acute
cardiovascular problem.
Consider the cost of all the unnecessary stress tests ordered,
coronary angiograms performed, and anti-platelet agents pre-
scribed for mild troponin elevations when the clinical situation
makes an acute cardiovascular problem very unlikely. The casual
use of the phrase non–ST-segment elevation myocardial infarc-
tion (NSTEMI) when the mild troponin elevation is not, in
fact, due to atherosclerotic coronary artery disease, creates its
own legacy. Think twice before attaching the NSTEMI label to
a patient with a mild troponin elevation much more likely to be
due to one or more of the conditions outlined by the authors in
Table 2 (1).
It is useful to draw an analogy between mild troponin elevations
and nonspecific ST-T changes on an electrocardiogram. I suggest
using the descriptive phrase “nonspecific mild troponin elevation”
if there is no compelling evidence to support a diagnosis of an ACS
and in patients with chronic cardiovascular disease or noncardiac
diseases. Doctors do not feel compelled to request an urgent
cardiology consult on every patient with nonspecific ST-T changes
on an electrocardiogram in the absence of any cardiac symptoms or
history of cardiac disease. Rather than allowing troponin to trump
common sense, we should inject more common sense into the
process of ordering a troponin level in the first place.
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